Astragalus
Astragalus membranaceus
TL;DR
Astragalus is a foundational Traditional Chinese Medicine tonic with substantial preclinical immunomodulatory data and thin human trial support. The best clinical evidence is as an adjunct during chemotherapy using injectable preparations. Oral supplementation for general immunity rests largely on tradition and mechanism.
Ideal For
- Adults interested in a traditional tonic with a strong preclinical rationale
- People recovering from prolonged illness or fatigue, as supportive care
- Those with diabetic kidney disease, under nephrology supervision
- Adults wanting a milder, non-stimulating alternative to ginseng
Avoid If
- You have an autoimmune condition — the immunostimulant profile is a genuine concern
- You are on immunosuppressants after organ transplant
- You are undergoing chemotherapy without your oncologist's knowledge
- You are pregnant or breastfeeding, where data are absent
- You expect the human evidence to match the marketing claims
Frequently Asked Questions
Overview
Astragalus membranaceus root supplies polysaccharides, saponins (astragalosides) and flavonoids, and its reputation in Chinese medicine as a qi tonic is centuries old. The laboratory picture is genuinely interesting: astragalus polysaccharides activate macrophages and dendritic cells via TLR4, astragaloside IV shows telomerase-activating properties that spawned the cycloastragenol longevity market, and multiple models show protection against nephropathy and cardiac remodelling. Translating that to human outcomes is where it thins out. The most cited clinical work is Chinese oncology literature using intravenous astragalus alongside platinum chemotherapy, where meta-analyses report reduced nausea and better performance status — but the trials are mostly small, unblinded and use a route of administration no consumer supplement matches. Randomised trials in diabetic nephropathy report reduced proteinuria and are somewhat more encouraging. For a healthy adult taking 500-3,000 mg of oral root extract for immune support, the honest statement is that the mechanistic case is strong and the outcome evidence is not yet there.
How It Works
- Astragalus polysaccharides activate macrophages and dendritic cells through TLR4 signalling
- Increases T-lymphocyte proliferation and immunoglobulin production in vitro
- Astragaloside IV activates telomerase in immune cells, the basis of cycloastragenol interest
- Reduces podocyte injury and proteinuria in diabetic nephropathy models
- Antioxidant flavonoids reduce oxidative stress in cardiac and renal tissue
- Modulates rather than uniformly stimulates — effects differ in immunosuppressed versus healthy states
Health Concerns Addressed
No linked health concerns yet.
Supporting Research10 studies
Astragalus (a traditional Chinese medicine) for treating chronic kidney disease
Zhang HW, Lin ZX, Xu C +2 more
Study quality was low overall. Our nominated primary outcomes of time to requirement for renal replacement therapy or initiation of dialysis and all-cause mortality were not reported in any of the included studies.
Efficacy of astragalus combined with renin-angiotensin-aldosterone system blockers in the treatment of stage III diabetic nephropathy: a systematic review and meta-analysis
Li Y, Wang Y, Zhang X +1 more
Astragalus added to RAAS blockade reduced urinary albumin excretion, serum creatinine and blood urea nitrogen.
Efficacy of Astragalus Membranaceus (Huang Qi) for Cancer-Related Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Studies
Sheng X, Yang L, Huang B +1 more
The addition of Astragalus membranaceus to the control group was effective in reducing cancer-related fatigue (SMD = -1.63, 95% CI [-1.90, -1.36], P < .00001).
Protective effect of Astragalus polysaccharide on diabetic nephropathy: a systematic review and meta-analysis reveals the efficacy and potential mechanisms
He Y, Zhao WJ, Yang ZC +1 more
Astragalus polysaccharide improved proteinuria and renal function markers, with mechanisms linked to oxidative stress and inflammation pathways.
Evidence of Astragalus injection combined platinum-based chemotherapy in advanced nonsmall cell lung cancer patients: A systematic review and meta-analysis
Cao A, He H, Wang Q +2 more
AGI combined chemotherapy could significantly improve the objective response rate (relative risk [RR] = 1.19, 95% confidence interval [CI] [1.06, 1.33], P = .002).
Effects of the traditional Chinese herb Astragalus membranaceus in patients with poststroke fatigue: A double-blind, randomized, controlled preliminary study
Liu CH, Tsai CH, Li TC +2 more
The difference in BFI scores between Visit 2 and Visit 1 was -17.83+/-17.70 in the TG, which was greater than that in the CG (-8.03+/-9.95; p=0.01).
Chronic fatigue syndrome post-COVID-19: triple-blind randomised clinical trial of Astragalus root extract
Banihashemi ZS, Azizi-Fini I, Rajabi M +1 more
Astragalus root extract has been shown to reduce chronic fatigue in nurses.
Astragalus polysaccharides improve adjuvant chemotherapy-induced fatigue for patients with early breast cancer
Shen WC, Chen SC, Wang CH +1 more
The mean change in the FGS and fatigue intensity did not significantly differ between both groups.
The clinical efficacy of Astragalus-containing Chinese patent medicines in the effective treatment of heart failure: A systematic review and network meta-analysis
Rui F, Di Y, Li C +1 more
Compared to using Western medicine (WM) alone, Astragalus Granule + WM ranked best for improving overall clinical efficacy rate.
Standardized astragalus extract for attenuation of the immunosuppression induced by strenuous physical exercise: randomized controlled trial
Latour E, Arlet J, Latour EE +2 more
AMR restored the immunological balance in strenuously trained athlets through a stabilization of NK and Treg cells.
Safety Information
Potential Side Effects
Well tolerated at typical doses. Mild gastrointestinal upset and loose stools occur. High doses may cause immune-related symptoms in sensitive individuals.
Contraindications
Autoimmune disease, immunosuppressive therapy, pregnancy and lactation, active transplant immunosuppression.
Drug Interactions
- Immunosuppressants including ciclosporin — opposing pharmacology
- Anticoagulants — theoretical additive effect
- Antidiabetic agents — additive glucose lowering reported in animal work
- Lithium — possible reduced clearance due to mild diuretic effect
- Cyclophosphamide — altered effect reported in preclinical models
Pregnancy & Breastfeeding
Pregnancy: insufficient_data
Breastfeeding: insufficient_data
Dosage Guidelines
Dosage Used in Studies
500-3000 mg
Best Time to Take
Morning, daily or seasonally
Best Form
Standardised root extract, 500-1,000 mg/day
Bioavailability
Astragaloside IV has poor oral bioavailability, reported below 3% in animal studies, which is a central reason positive clinical trials used injectable preparations. Polysaccharides act largely on gut-associated lymphoid tissue rather than being absorbed intact.
Forms Compared
Standardised root extract
Whole root decoction
Cycloastragenol / TA-65
Injectable astragalus
Astragalus in adaptogen blends
Food & Timing
With or without food; taken in the morning in traditional practice as a qi tonic
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.